drugset / Trial / NCT07165847
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Phase 2
Recruiting
40 enrolled
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
RandomizedParallel-groupSingle-blindTreatment
Summary
Neoadjuvant radiotherapy plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Timeline
- Start
- 2025-07-23
- Primary completion
- 2028-09-23
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Subject | Tegafur | Unknown | 40 mg | Oral |
| Subject | Tegafur | Unknown | 50 mg | Oral |
| Subject | Tegafur | Unknown | 60 mg | Oral |
| Subject | Tuvonralimab | Monoclonal antibody | 5 mg/kg | Intravenous |